Two yeast recombinant vaccines were compared: the Russian hepatitis B
Combiotech vaccine in a dose of 20 mg and the Recombivax-HB vaccine in
a dose of 10 mg manufactured in the USA (Merk, Sharp and Dohme Ltd.).
Both agents were found safe and low reactogenic. After a course of 3
vaccinations with the Russian vaccine 92.5 to 97.5% subjects vaccinate
d after the 0-1-2 months and 0-1-6 months protocols had high levels of
specific antibodies. In the group vaccinated with the American vaccin
e, antibodies to HBsAg were found in the sera of 95 to 100% subjects.
These results demonstrate high immunological activity of both Russian
and American vaccines.